Role of conventional therapies in the era of biological treatment in Crohn’s disease

作     者：Paolo Gionchetti Carlo Calabrese Rosy Tambasco Ramona Brugnera Giulia Straforini Giuseppina Liguori Giulia Spuri Fornarini Donatella Riso Massimo Campieri Fernando Rizzello 

作者机构：Department of Clinical MedicineUniversity of Bologna40138 BolognaItaly 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2011年第17卷第14期

页      面：1797-1806页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：Supported by MIUR  PRIN 2008 (MC) 

主　　题：Crohn’s disease Sulfasalazine 5-Aminosalicylic acid Azathioprine 6-Mercaptopurine Biological therapies Anti-tumor necrosis facto-α 

摘      要：Outstanding progress regarding the pathophysiology of Crohn s disease (CD) has led to the development of innovative therapeutic concepts. Numerous controlled trials have been performed in CD. This review concentrates on the results of randomized,placebo-controlled trials,and meta-analyses when available,that provide the highest degree of evidence. Current guidelines on the management of CD recommend a step-up approach to treatment involving the addition of more powerful therapies as the severity of disease and refractoriness to therapy increase. The advent of biological drugs has opened new therapeutic horizons for treating CD,modifying the treatment goals. However,the large majority of patients with CD will be managed through conventional therapy,even if they are a prelude to biological therapy.